Previous 10 | Next 10 |
On June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Boar...
FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced new da...
NeoGenomics (NASDAQ:NEO) said it received CAP certification with zero deficiencies paving the way for it to offer its pharmaceutical partners an option to use its Suzhou laboratory for trials relating to patients in China, from early discovery through trial work in oncology drug developm...
CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D FORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, has successfully received their CAP certificati...
The Carillon Family of Funds spans a range of investment objectives and asset classes designed for long-term investors. Inflation concerns and accelerating expectations of interest rate hikes by the U.S. Federal Reserve sent equity markets in a downward spiral to start the new year. ...
NEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), CIRCOR International, Inc. (NYSE: CIR), and NeoGeno...
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
NeoGenomics (NASDAQ:NEO) appointed Lynn Tetrault, Esq., current Executive Chair and Principal Executive Officer, as board chair and interim CEO, effective May 12. Ms. Tetrault has been serving as Executive Chair since March when the CEO agreed to step down. "With Lynn serving as Int...
FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") together with collab...
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the depa...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...